Skip to content

Qureight raises £1.5m funding to curate complex disease data

Qureight funding
Image credit: Qureight

UK clinical data analytics company Qureight has raised £1.5m in a seed funding round to curate what it calls the largest collection of complex disease datasets. 

Playfair Capital led the investment round with participation from Life Sciences funds Meltwind, Ascension, and Cambridge Angels. 

Founded by Alessandro Ruggiero and Muhunthan Thillai, Qureight uses cloud-based technology to structure datasets relating to complex diseases. 

The Cambridge-headquartered startup’s proprietary technology allows researchers and scientists to analyse and track disease progression and drug response in patients with complex diseases. Bio-pharma and academic institutions can use the platform to obtain new insights into diseases and responses to treatment.

The goal is to reduce the costs of bringing complex, life-saving drugs to market.

One of Qureight’s early targets is Idiopathic Pulmonary Fibrosis (IPF) – a condition that causes scar tissue to grow inside the lungs and makes it hard to breathe. It can also occur as a consequence of Covid-19. 

Last year, Qureight claims it became the first to integrate complex data sets and software algorithms across Europe. The work revealed the changes in blood distribution within the lungs in Covid-19 infection, which in turn opened the door to newer ways of treating patients by targeting the lung’s blood supply.

“Existing treatments for lung fibrosis are costly and clinical trials to find new drugs are often very large – needing many patients to look for an outcome,” said Qureight co-founder Dr Thillai. “Qureight’s platform technology will allow biopharma companies to recruit fewer patients for clinical trials and more precisely target the right kind of patients – saving money and producing better outcomes with a personalised approach to drug development.”

Qureight co-founder and chief scientific officer Dr Alessandro Ruggiero – also a radiology consultant in Cambridge, said: “Our next targets are pulmonary hypertension and adverse drug effects in complex lung cancer patients. This funding will allow us to use our platform to work with our biopharma partners to accelerate drug development in these areas.”